# The Efficacy and Safety of OROSARTAN® Versus CODIOVAN® in Patients With Essential Hypertension Uncontrolled With Monotherapy

Study · id `cardio:ct-nct02433119` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02433119](<https://clinicaltrials.gov/study/NCT02433119>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02433119

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 238 participants.

## Technical summary

Registry record NCT02433119. Randomized; quadruple masking; primary purpose treatment. Start 2015-03-16 (actual); primary completion 2016-09-08 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 238 participants (enrolled count; ClinicalTrials.gov record NCT02433119, source copy `cardio:ctgov-nct02433119-2017-04-12`, retrieved 2026-10-26)
- Started: 2015-03-16 (actual) (ClinicalTrials.gov record NCT02433119, source copy `cardio:ctgov-nct02433119-2017-04-12`, retrieved 2026-10-26)
- Primary completion: 2016-09-08 (actual) (ClinicalTrials.gov record NCT02433119, source copy `cardio:ctgov-nct02433119-2017-04-12`, retrieved 2026-10-26)
- Completion: 2016-09-08 (actual) (ClinicalTrials.gov record NCT02433119, source copy `cardio:ctgov-nct02433119-2017-04-12`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT02433119, source copy `cardio:ctgov-nct02433119-2017-04-12`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02433119-2017-04-12`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Efficacy and Safety of OROSARTAN® Versus CODIOVAN® in Patients With Essential Hypertension Uncontrolled With Monotherapy
- Condition: Hypertension
- Intervention (Drug): OROSARTAN® 5/160mg
- Intervention (Drug): CODIOVAN® 160/12.5mg
- Lead sponsor: Dong-A ST Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Dong-A ST Co., Ltd. (`cardio:org-dong-a-st-co-ltd`)

## Provenance

Content hash: 68c1faac552809b7c60fb0a8a12b4f76fe9b9963bfe1de5d15e88161f0c44188
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
